Chiasma Set to Join Russell 3000® Index
27 juin 2019 16h10 HE
|
Chiasma, Inc.
WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Provides Update on Ongoing Mycapssa® Phase 3 Clinical Trials
27 juin 2019 16h05 HE
|
Chiasma, Inc.
On track with U.S. Phase 3 CHIASMA OPTIMAL trial; data now expected by mid-Q3 2019 Target enrollment completed in ongoing Phase 3 MPOWERED™ trial; data expected in 2H 2020 WALTHAM, Mass., June 27,...
Chiasma Strengthens Leadership Team Ahead of Anticipated Commercial Availability of Mycapssa®
05 juin 2019 16h05 HE
|
Chiasma, Inc.
Appoints pharma commercial veteran Raj Kannan as Chief Executive Officer Current CEO Mark Fitzpatrick to retain the role of President WALTHAM, Mass., June 05, 2019 (GLOBE NEWSWIRE) -- Chiasma,...
Chiasma and Lonza Announce Progression of Oral Octreotide Capsules Development and Definitive Commercial Supply Agreement
14 mai 2019 16h05 HE
|
Chiasma, Inc.
Chiasma recently completed enrollment of its CHIASMA OPTIMAL Phase 3 clinical trial of octreotide capsules, the first potential oral somatostatin analog for the maintenance treatment of...
Chiasma Reports First Quarter 2019 Results
09 mai 2019 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma to Report First Quarter Financial Results on May 9, 2019
30 avr. 2019 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Closing of $34.5 Million Offering of Common Stock and Full Exercise of Underwriters’ Option
03 avr. 2019 09h25 HE
|
Chiasma, Inc.
WALTHAM, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Pricing of Underwritten Public Offering of $30.0 Million of Common Stock
29 mars 2019 09h25 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Proposed Offering of Common Stock
28 mars 2019 16h01 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...
Chiasma Announces Three Poster Presentations at ENDO 2019
21 mars 2019 16h05 HE
|
Chiasma, Inc.
WALTHAM, Mass., March 21, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic...